Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review

References

• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. CDC 2003
   Google Scholar
• Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002;50:1–85
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Diabetes Public Health Resource. Oct 27, 2003
   Google Scholar
• American Diabetes Association. American Diabetes Association: clinical practice recommendations. Diabetes Care 2003; 26(Suppl 1):S1–S156
   Google Scholar
• Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J 2001;322:15–8
   PubMed Web of Science ®Google Scholar
• National Institute of Diabetes and Digestive and Kidney Diseases. National diabetes statistics fact sheet: general information and national estimates on diabetes in the United States. 2003:1–14
   Google Scholar
• Kazlauskaite R, Fogelfeld L. Insulin therapy in type 2 diabetes. Dis Mon 2003;49:377–420
   PubMed Web of Science ®Google Scholar
• Wright A, Burden ACF, Paisey RB, et al. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6years in patients with type 2 diabetes in the UK [prospective diabetes study (UKPDS 57)]. Diabetes Care 2002;25: 330–6
   Google Scholar
• American Diabetes Association (ADA). Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26\(Suppl 1):S33–S50
   Google Scholar
• AACE. American College of Endocrinology Consensus Statement on Guidelines for Glycemic Control. Endocrine Practice 2002;8(Suppl 1):5–11
   PubMedGoogle Scholar
• American Diabetes Association (ADA). Standards of medical care in diabetes. Diabetes Care 2004;27 Suppl 1:S15–S35
   Google Scholar
• Nathan DM, McKitrick C, Larkin M, et al. Glycemic control in diabetes mellitus: have changes in therapy made a difference? Am J Med 1996;100:157–63
   PubMed Web of Science ®Google Scholar
• U.K. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease [abstract]. Diabetes 1995;44: 1249–58
   Google Scholar
• Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm 2003;9:309–16
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837–53
   Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977–86
   Google Scholar
• Adverse events and their association with treatment regimens in the diabetes control and complications trial [abstract]. Diabetes Care 1995;18:1415–27
   PubMed Web of Science ®Google Scholar
• Fritsche A, Haring H-U, Togel E, Schweitzer M-A. Treat-to-target with add-on basal insulin – can insulin glargine reduce the barrier to target attainment? American Diabetes Association 63rd Annual Scientific Sessions. 2003
   Google Scholar
• Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002;45:937–48
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Jackson RA. What’s so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clinical Diabetes 2004;22:147–50
   Google Scholar
• Tattersall RB. Diabetes in the elderly – a neglected area? Diabetologia 1984;27:167–73
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Insulin delivery. 11–14–2003
   Google Scholar
• Rosenstock J. Insulin therapy: optimizing control in type 1 and type 2 diabetes. Clin Cornerstone 2001;4:50–64
   PubMedGoogle Scholar
• Edelman SV, Henry RR. Diagnosis and management of Type 2 diabetes. Insulin therapy. Caddo (OK): Professional Communications, Inc.; 2002. p. 121–48
   Google Scholar
• Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl 2000:3–13
   PubMedGoogle Scholar
• Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of endocrine pancreas. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman’s the pharmacological basis of therapeutics. New York (NY): McGraw Hill; 2001. p. 1679–714
   Google Scholar
• Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone [Glimepiride Combination Group]. Diabetes Care 1998;21:1052–7
   PubMed Web of Science ®Google Scholar
• Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am 1997;26:659–77
   PubMed Web of Science ®Google Scholar
• Texas Diabetes Council. Insulin algorithm for type 2 diabetes mellitus in children and adults. 45–11647. 6–30–2004
   Google Scholar
• Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142–8
   PubMed Web of Science ®Google Scholar
• LANTUS® [package insert] Aventis Pharmaceuticals Inc, Kansas City, MO (insulin glargine [rDNA origin] injection). Accessed August 2004. www.Lantus.com. 2004
   Google Scholar
• Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23: 1130–6
   Google Scholar
• Rosenstock J, Riddle MC. Treatment to target study: timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naive patients with type 2 diabetes on oral agents [abstract]. Diabetes 2002;51(Suppl):A482
   Google Scholar
• Riddle MC, Rosenstock J. Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract]. Diabetes 2002;51(Suppl):A113
   Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–24
   PubMed Web of Science ®Google Scholar
• Malone JK, Sun B, Matto V, et al. Humalog [reg] Mix 75/25 [tm] twice daily improves glycemic control compared with NPH twice daily in patients with type 2 diabetes [abstract 1948-PO]. Diabetes 2002;51(Suppl 2):A474
   Google Scholar
• Leahy JL. Intensive insulin therapy in Type 1 diabetes mellitus. In: Leahy JL, Cefalu WT, editors. Insulin therapy. Marcel Dekker; 2002. p. 87–112
   Google Scholar
• Fritsche A, Schweitzer MA, Häring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138: 952–9
   Google Scholar
• Busch K, Fritsche A, Haring H-U, et al. Insulin glargine plus oral therapy in patients with type 2 diabetes allows flexible dosing and leads to improved metabolic control with less hypoglycemia versus NPH insulin [abstract 1918-PO]. Diabetes 2003;52 (Suppl 1):A443
   Google Scholar
• Adult Treatment Panel III. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults [final report]. Circulation 2002;106:3143–421
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080–6
   Google Scholar
• Yki-Jarvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130: 389–96
   Google Scholar